July 7, 2021

Neurolief Announces Exclusive Licensing Agreement with NeuroFront for Development and Commercialization of Relivion® in Greater China and South Korea

TAMPA, Fla. & NETANYA, Israel–(BUSINESS WIRE)–Neurolief, an Israel-based company pioneering neuromodulation for the treatment of chronic neurological and neuropsychiatric disorders, and NeuroFront, a clinical stage biotech company focusing on innovative neuroscience therapies, jointly announced an exclusive licensing agreement for NeuroFront to develop and commercialize Relivion, non-invasive medical devices for the treatment of migraine and depression, in Greater China (mainland China, Hong

Leave Comment

Your Name *
Your Email *
Your Website
Comment *